Proper timing, dosing protocols, and understanding the synergies between these compounds can significantly enhance body recomposition outcomes
The review also notes a temporary worsening of diabetes-related retinopathy during rapid glycemic improvement, an increased aspiration risk from delayed gastric emptying, and the need to protect against nutritional deficiencies and loss of muscle or bone mass during rapid weight loss
[1] Because no GLP-1 patches are currently FDA-approved or commercially available , there is no established clinical protocol for their application
Consequently, there are no data on short-term or long-term effects in humans, the potential impact on receptor interaction, toxicity, or immune reactions
GLP-1 face refers to the facial volume loss, skin laxity, and accelerated signs of aging observed in patients using GLP-1 receptor agonists for weight loss or diabetes management
Open-field test Locomotor activity was evaluated using an open-field test